Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled ...
Larimar Therapeutics LRMR is a clinical-stage company making medicines for rare diseases. The company has a Zacks Rank #1 (Strong Buy). Here we discuss some reasons why investing in LRMR stock now is ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The company is hosting a conference call and webcast to provide regulatory updates on its clinical development program for nomlabofusp, indicating transparency and engagement with stakeholders. This ...
Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had remained in part on the program since 2021. The rare disease biotech can now ...
BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Larimar Therapeutics (NASDAQ:LRMR) lost ~29% on Monday after the clinical-stage biotech posted its Q1 financials for 2023 alongside Phase 2 topline data for its lead candidate CTI-1601 in Friedreich’s ...
Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its ...
Larimar Therapeutics held its breath for over a year, but the FDA has finally given the biotech a green light to continue trials of its lead, and only, asset this year. To coincide with its ...
The Dominican Republic wants jewelers to love larimar, the national stone. But authorities shut the mine temporarily after two fatal accidents. The inspiration for Joarla Caridad’s Pool Ring with ...
The clinical hold means that Bala Cynwyd, Pennsylvania-based Larimar can’t proceed with further tests of the drug, CTI-1601, in humans, including a study that was expected to start in the second half ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results